Statins From Lipid-Lowering Benefits to Pleiotropic Effects
Statins are now the most widely used agents in patients with dyslipidemia, atherosclerosis and cardiovascular disease. However, their effects and mechanisms have not been fully investigated, and research continues to reveal new aspects of statins. The up-to-date content of this book will be useful t...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
IntechOpen
2023
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 02269namaa2200541uu 4500 | ||
|---|---|---|---|
| 001 | doab135123 | ||
| 003 | oapen | ||
| 005 | 20240307 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 240307s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a 9781837697618 | ||
| 020 | |a 9781837697625 | ||
| 020 | |a 9781837697632 | ||
| 020 | |a intechopen.1001540 | ||
| 024 | 7 | |a 10.5772/intechopen.1001540 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MKG |2 bicssc | |
| 720 | 1 | |a Liu, Donghui |4 edt | |
| 720 | 1 | |a Liu, Donghui |4 oth | |
| 245 | 0 | 0 | |a Statins |b From Lipid-Lowering Benefits to Pleiotropic Effects |
| 260 | |b IntechOpen |c 2023 | ||
| 300 | |a 1 online resource (172 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a Statins are now the most widely used agents in patients with dyslipidemia, atherosclerosis and cardiovascular disease. However, their effects and mechanisms have not been fully investigated, and research continues to reveal new aspects of statins. The up-to-date content of this book will be useful to physicians in cardiovascular disease and geriatrics, and to academics conducting research on statins. It includes novel perspectives leading to new insights and advancing existing knowledge on statins. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/3.0/ |2 cc |u https://creativecommons.org/licenses/by/3.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a ACLY Inhibitors | ||
| 653 | |a ASCVD | ||
| 653 | |a Endothelial Cell | ||
| 653 | |a HDL-C | ||
| 653 | |a Inflammation | ||
| 653 | |a LDL-C | ||
| 653 | |a Liver Injury | ||
| 653 | |a Muscle Symptoms | ||
| 653 | |a New-Onset Diabetes | ||
| 653 | |a NPC1L1 Inhibitor | ||
| 653 | |a PCSK9 Inhibitors | ||
| 653 | |a Statins | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/135123 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://intech-files.s3.amazonaws.com/a043Y00000vBvowQAC/0014074_Authors_Book%20%282023-06-12%2009%3A05%3A28%29.pdf |7 0 |z Open Access: DOAB, download the publication |